Cargando…
Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy
Rare disease clinical trials are constrained to small sample sizes and may lack placebo-control, leading to challenges in drug development. This paper proposes a Bayesian model-based framework for early go/no-go decision making in rare disease drug development, using Duchenne muscular dystrophy (DMD...
Autores principales: | Lennie, Janelle L., Mondick, John T., Gastonguay, Marc R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049549/ https://www.ncbi.nlm.nih.gov/pubmed/35482633 http://dx.doi.org/10.1371/journal.pone.0247286 |
Ejemplares similares
-
Decision-Making And Selection Bias in Four Observational Studies on Duchenne and Becker Muscular Dystrophy
por: Naarding, Karin J., et al.
Publicado: (2020) -
Drug development progress in duchenne muscular dystrophy
por: Deng, Jiexin, et al.
Publicado: (2022) -
Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012) -
Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021) -
Gigantic Stomach: A Rare Manifestation of Duchenne Muscular Dystrophy
por: Dhaliwal, Amaninder, et al.
Publicado: (2019)